Project
STEP 4
Completed · 2018 until 2020
Bilz Stefan, Sigrist Sarah, Aczel Stefan, Räss Andrea
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2018
End Date
2020
Financing
Industry
Homepage
Brief description/objective
Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period